Vertex Pharmaceuticals Incorporated · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-07-10$479.53 RISE2025-09-24$376.62 PEAK2025-12-03$463.13 146d | -21.5% 76d | Missed | Missed | — | — | +23.0% 70d | Missed |
DROP2025-04-30$509.50 RISE2025-08-08$366.54 PEAK2025-10-22$426.44 175d | -28.1% 100d | Missed | Missed | — | — | +16.3% 75d | Missed |
DROP2024-11-08$516.74 RISE2024-12-19$396.64 PEAK2025-03-17$513.76 129d | -23.2% 41d | Missed | Missed | — | — | +29.5% 88d | Missed |
DROP2022-04-13$290.93 RISE2022-06-13$245.39 PEAK2022-08-15$305.53 124d | -15.7% 61d | Missed | Missed | — | — | +24.5% 63d | Missed |
DROP2022-04-13$290.93 RISE2022-05-11$234.96 PEAK2022-07-08$294.29 86d | -19.2% 28d | Missed | Missed | — | — | +25.3% 58d | Missed |
DROP2021-06-10$216.77 RISE2021-10-05$177.01 PEAK2021-12-23$223.45 196d | -18.3% 117d | 2021-07-01 $202.21 | 2021-12-23 $223.45 | 62Deep Value | 46Watch | +26.2% 79d | +10.5% Held 175d |
DROP2020-07-20$303.10 RISE2020-10-29$207.01 PEAK2021-01-25$241.31 189d | -31.7% 101d | Missed | Missed | — | — | +16.6% 88d | Missed |
DROP2020-02-11$247.81 RISE2020-03-16$199.77 PEAK2020-05-15$288.69 94d | -19.4% 34d | Missed | Missed | — | — | +44.5% 60d | Missed |
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 4.1% return has trailed the S&P 500 by 6.2 percentage points.
Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the 12 Most Profitable Stocks to Invest In. On May 21, 2026, Vertex Pharmaceuticals (NASDAQ:VRTX) announced that Health Canada accepted for review a New Drug Submission for suzetrigine for the treatment of moderate-to-severe acute pain in adults. Vertex said suzetrigine is a selective NaV1.8 pain signal inhibitor and represents […]
Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.
If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading the way, the biotech space is more than worth exploring, especially as some of the AI benefits start to trickle downstream towards biotech ... These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth
The search is still on for an opioid alternative and many companies are betting on ion channel drugs to fill the gap.
The Investment Committee debate the latest Calls of the Day.
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that Health Canada has accepted for review a New Drug Submission (NDS) for suzetrigine for the treatment of moderate-to-severe acute pain in adults. Suzetrigine is a selective NaV1.8 pain signal inhibitor that represents a new class of oral pain medicine; it is not an opioid or a nonsteroidal anti-inflammatory drug (NSAID). If approved by Health Canada, suzetrigine has the potential to be the first new class of medicine in Canada to treat acu
The global polycystic kidney disease (PKD) market is expanding rapidly due to rising prevalence, advanced treatments, and increased awareness. The growing cases of chronic kidney diseases (CKD) including PKD, driven by factors like genetic mutations, hypertension, and diabetes, contribute to the market's growth. Innovations in diagnostics, such as MRI and genetic testing, facilitate early intervention in PKD cases. The approval of tolvaptan and ongoing research into therapies like lixivaptan off
– Suzetrigine, a selective pain signal inhibitor, has the potential to treat millions of Canadians who suffer from moderate-to-severe acute pain each year –TORONTO, May 21, 2026 /CNW/ - Vertex Pharmaceuticals
Vertex Pharmaceuticals (VRTX) stock has moved lower recently, with the price down about 2% over the past month and roughly 8% over the past 3 months, prompting closer attention from investors. See our latest analysis for Vertex Pharmaceuticals. Zooming out, Vertex’s recent share price weakness, including a 1-day share price return of down 0.89% and a 7-day share price return of down 4.99%, sits against a 5-year total shareholder return of 108.14%. This points to fading short term momentum...
Vertex Pharmaceuticals (VRTX) stock has moved lower recently, with the price down about 2% over the past month and roughly 8% over the past 3 months, prompting closer attention from investors. See our latest analysis for Vertex Pharmaceuticals. Zooming out, Vertex’s recent share price weakness, including a 1-day share price return of down 0.89% and a 7-day share price return of down 4.99%, sits against a 5-year total shareholder return of 108.14%. This points to fading short term momentum...
Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commercial franchises.
Vertex Pharmaceuticals Incorporated (VRTX) RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 2:35 PM EDTCompany ParticipantsCharles Wagner...
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host
CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| VRTX | +5.57% | -7.92% | -1.28% | +1.24% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +2.60% | -2.20% | +2.16% | -11.45% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| CapResearch | fundamental | 21.13M | $9.43B | 1.46% | Added+22.0% | 2026-03-31 |
| StateStreet | passive | 11.73M | $5.24B | 0.18% | Unchanged | 2026-03-31 |
| Wellington | fundamental | 3.21M | $1.43B | 0.27% | Trimmed-15.9% | 2026-03-31 |
| FidelityFMR | fundamental | 2.02M | $902.13M | 0.05% | Trimmed-8.7% | 2026-03-31 |
| RenTech | quant | 421.7K | $188.30M | 0.29% | Trimmed-16.5% | 2026-03-31 |
| TwoSigma | quant | 378.1K | $168.86M | 0.14% | Added+9001.0% | 2026-03-31 |
| DEShaw | quant | 249.0K | $111.17M | 0.07% | New | 2026-03-31 |
| Bridgewater | macro | 13.4K | $5.96M | 0.03% | Trimmed-51.4% | 2026-03-31 |
| TRowePrice | fundamental | 1.76M | $785.97K | 0.09% | Trimmed-22.8% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-19 | Bozic Carmen | EVP and CMO | S Open-market sale | 1,354 | $453.45 | −$614.0K |
| 2026-05-19 | Bunnage Mark E. | EVP, Chief Scientific Officer | S Open-market sale | 33 | $453.45 | −$15.0K |
| 2026-05-14 | Bozic Carmen | EVP and CMO | S Open-market sale | 6,988 | $450.00 | −$3.14M |
| 2026-05-05 | Bhatia Sangeeta N. | Director | S Open-market sale | 318 | $423.73 | −$134.7K |
| 2026-05-05 | Bhatia Sangeeta N. | Director | A Grant / award | 943 | — | +$0 |
| 2026-05-05 | CARNEY LLOYD | Director | A Grant / award(deriv) | 2,866 | — | +$0 |
| 2026-05-05 | Garber Alan M | Director | A Grant / award(deriv) | 1,433 | — | +$0 |
| 2026-05-05 | Garber Alan M | Director | A Grant / award | 472 | — | +$0 |
| 2026-05-05 | Lagarde Michel | Director | A Grant / award(deriv) | 2,866 | — | +$0 |
| 2026-05-05 | Liu Joy | EVP and Chief Legal Officer | S Open-market sale | 1,104 | $425.02 | −$469.2K |
| 2026-05-05 | MCKENZIE DIANA | Director | A Grant / award(deriv) | 796 | — | — |
| 2026-05-05 | MCKENZIE DIANA | Director | D Disposition (other) | 796 | — | — |
| 2026-05-05 | MCKENZIE DIANA | Director | A Grant / award | 943 | — | +$0 |
| 2026-05-05 | SACHS BRUCE I | Director | A Grant / award(deriv) | 2,866 | — | +$0 |
| 2026-05-05 | Schneider Jennifer | Director | A Grant / award(deriv) | 796 | — | — |
| 2026-05-05 | Schneider Jennifer | Director | A Grant / award(deriv) | 1,433 | — | +$0 |
| 2026-05-05 | Schneider Jennifer | Director | D Disposition (other) | 796 | — | — |
| 2026-05-05 | Schneider Jennifer | Director | A Grant / award | 472 | — | +$0 |
| 2026-05-05 | Thornberry Nancy | Director | A Grant / award(deriv) | 398 | — | — |
| 2026-05-05 | Thornberry Nancy | Director | A Grant / award(deriv) | 1,433 | — | +$0 |
| 2026-05-05 | Thornberry Nancy | Director | D Disposition (other) | 398 | — | — |
| 2026-05-05 | Thornberry Nancy | Director | A Grant / award | 472 | — | +$0 |
| 2026-05-05 | Upadhyay Suketu | Director | A Grant / award(deriv) | 796 | — | — |
| 2026-05-05 | Upadhyay Suketu | Director | A Grant / award(deriv) | 2,866 | — | +$0 |
| 2026-05-05 | Upadhyay Suketu | Director | D Disposition (other) | 796 | — | — |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-03upcoming | 4.73 | — | — |
| 2026-05-04 | 4.31 | 4.47 | +3.81% |
| 2026-02-12 | 5.15 | 5.03 | -2.30% |
| 2025-11-03 | 4.58 | 4.80 | +4.87% |
| 2025-08-04 | 4.25 | 4.52 | +6.33% |
| 2025-05-05 | 4.29 | 4.06 | -5.44% |
| 2025-02-10 | 4.02 | 3.98 | -1.00% |
| 2024-11-04 | 4.13 | 4.38 | +5.96% |
| 2024-08-01 | -11.75 | -12.83 | -9.17% |
| 2024-05-06 | 4.06 | 4.76 | +17.28% |
| 2024-02-05 | 4.09 | 4.20 | +2.78% |
| 2023-11-06 | 3.97 | 4.08 | +2.74% |
| 2023-08-01 | 3.88 | 3.89 | +0.15% |
| 2023-05-01 | 3.00 | 3.05 | +1.55% |
| 2023-02-07 | 3.51 | 3.76 | +7.05% |
| 2022-10-27 | 3.64 | 4.01 | +10.07% |